Group1321316319-285.png

About
Full-Life Technologies

Full-Life Technologies Limited ("Full-Life") is a fully integrated global radiotherapeutics company with operations in Belgium, Germany, and China. We seek to own the entire value chain for radiopharmaceutical research & development, production & commercialization in order to deliver clinical impact for patients. The company plans to attack core issues affecting radiopharmaceuticals today through innovative research that targets the treatments of tomorrow.

We are comprised of a team of fast-moving entrepreneurs and scientists with a demonstrated track record in the life sciences, as well as radioisotope research and clinical development.

0
SCROLL

Team

    • 4-739.png
      Lanny Sun

      Co-founder, Chairman & Chief Executive Officer

    • 7-118.png
      Steffen Heeger, MD, Ph.D.

      Chief Medical Officer

    • 6-672.png
      Fa Liu, Ph.D.

      Chief Scientific Officer

    • 5-492.png
      Hong-hoi Ting, D.Phil.

      Co-founder, Board Member & Chief Strategy Officer

    • 2-831.png
      Philippe van Put

      General Manager, Europe

    • 1-906.png
      Nicholas Wong, Ph.D.

      Co-founder & Chief Operating Officer

    • 3-654.png
      Julie Wu

      Chief Financial Officer

    • 8.png
      James McCarter, Ph.D.

      Vice President & Head of Radioisotope Technology Research

Milestones

  • 2024. 1

    Full-Life completed $63.3 million financing, comprised of $47.3 million in Series B equity financing and $16 million in loan facilities. 

    2024. 1
  • 2023. 12

    Full-Life Technologies Breaks Ground for GMP Manufacturing Facility in Belgium to Advance Its End-to-end Solution for Radiopharmaceuticals.

    2023. 12
  • 2023. 5

    Full-Life Technologies completed land purchase in Belgium to establish GMP manufacturing facility for radiopharmaceutical drug production.

    2023. 5
  • 2023. 1

    Full-Life Technologies Announces Appointment of Chief Medical Officer and Chief Scientific Officer.

    2023. 1
  • 2022.11

    Full-Life Technologies to Acquire Focus-X Therapeutics, Bolstering Peptide-Focused Radiopharmaceutical Pipeline.

    2022.11
  • 2022. 8

    Full-Life Technologies Announces Key Leadership Appointments and the Establishment of a Radioisotope Technology Advisory Board.

    2022. 8
  • 2022. 5

    Full-Life Technologies completed $37 million in series A round financing.

    2022. 5
  • 2022. 1

    Full-Life Technologies announced four key appointments to its executive team.

    2022. 1
  • 2021. 12

    Full-Life Technologies completed $10 million in seed round financing.

    2021. 12
  • 2021. 8

    Full-Life Technologies was Founded.

    2021. 8